Clinical Experience with the Preparation Miacalcic Nasal Spray

Overview

To a group of 120 patients daily thyrocalcitonin (Miacalcic nasal spray, Novartis, CH) was administered, 200 i.u. = one spray along with 1000 mg Ca (Maxi-Kalz 500, Asta Medica, A) 2x1 tablet per day in water. In a group of 46 patients with different forms of osteoporosis the axial density increased after one year only by 1.86% AM, but during this period only three new vertebral fractures occurred (6.52%). In 10 bone tumours or metastases the pain intensity declined and improvement occurred already round the 5th day. In 23 women after total goitrectomy the axial density increased after one year of treatment by 3.99% AM (differs statistically significantly from other osteoporoses). In 18 subjects with m. Sudeck the mean period of treatment was 33 days. In 14 patients with acute pancreatitis the serum amylase and urinary level declined by the 5th day. Pain ceased already on the second day of treatment. In 9 subjects with m. Paget the activity of serum ALP and its bone isoenzyme declined within three weeks.

Key words:
thyrocalcitonin - nasal spray - osteoporosis - bone tumours - goitrectomy - m. Sudeck - m. Paget - acute pancreatitis.